Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, highlights data coming from a Phase I/II study (NCT03106415) of pembrolizumab in combination with the MEK inhibitor, binimetinib, in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The study showed that this combination was well-tolerated, and that in line with pre-clinical data MEK inhibition can restore T-cell function. Additionally, promising activity was observed in patients with low tumor infiltrating lymphoctyes (TILs) and PD-L1 negative, particularly in patients without liver metastases. Future larger clinical trials are warranted to further evaluate the efficacy of this chemotherapy-free combination. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.